The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships.
about
Pharmacodynamic modeling of adverse effects of anti-cancer drug treatmentEarly QT assessment--how can our confidence in the data be improved?Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affectA comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males.Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect.Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation.Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals.Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses.Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice.Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models.Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.Dosage regimen design: pharmacodynamic considerations.An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditionsConcentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review.Cardiovascular Safety Assessment in Early-Phase Clinical Studies: A Meta-Analytical Comparison of Exposure-Response Models.The place of simultaneous pharmacokinetic pharmacodynamic modeling in new drug development: trends and perspectives.Concepts and usefulness of pharmacokinetic-pharmacodynamic modelling.Current concepts in the pharmacotherapy of pseudobulbar affect.Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.Antiarrhythmic therapy: clinical pharmacology update.Metabolites of cardiac antiarrhythmic drugs: their clinical role.Methodological approach in the study of anticancer drug metabolism: qualitative considerations.Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM.The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine.Drug metabolite concentration-time profiles: influence of route of drug administration.DRUGMODEL.Scientific white paper on concentration-QTc modeling.Pharmacodynamic modeling of thiopental anesthesia.Pharmacokinetics and pharmacodynamics of intravenous cibenzoline in normal volunteers.Pharmacokinetic and pharmacodynamic modeling of cibenzoline plasma concentrations and antiarrhythmic effect.Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization*
P2860
Q26766318-93DF903B-CC23-4F58-A3A4-601BC4CB807CQ27020964-DDFA5040-B5FE-490D-BD45-C3B3A2557C52Q28293218-C0DCB931-CC58-4600-9F76-E62C4E94C685Q28378690-C12A4316-EB74-4DBD-A6DD-419434E818FCQ30634431-A79A33AC-8E01-435D-B416-E1597FAC8D2CQ31026162-71707BF3-5585-4EE5-A29F-008995DD5153Q34603893-FD27B56C-4C29-4A11-A649-852305804435Q35827376-FBEFB1ED-B188-4974-AB6F-E28A739B5E64Q35981946-494EA694-EF0D-4BD3-9E7D-201F316335FCQ36090728-D45BFB1B-A2BB-4896-9347-C49B7D4B86FBQ36341664-FEB86737-6548-47C5-9B28-FEB1C9D909ABQ36363552-48BFF5DE-1125-44CE-92FC-A5EA3FC0FB52Q36551001-AE55E391-A140-459E-B0F1-77EB74C010E2Q37038099-9FEBBAE2-C371-42C8-BD32-EF81A24D1006Q37461720-8A085C39-D413-47F1-B52E-1DEBE1485604Q37799266-9511B035-65A1-43D5-8645-C767DD74BDCBQ37799303-37F778D6-3140-41A4-9D50-955F31ED2DD6Q37895256-06A10EF4-D939-408D-8BF2-0845ABBAB4A8Q38204833-86AB4A41-9DE7-4901-8F4C-029CFB794DFDQ40187593-59B087BA-60CA-45CC-9E81-8F92CBAA6FE1Q40215729-D30A1A96-09BE-4F2A-BEB8-B8CB6465D9C0Q40884171-1E796BC1-9DDD-4CA6-9399-161278E31BF6Q41660943-D781D5C7-9B45-4502-B042-81C8F8C16E4EQ41996767-30A30FC6-EC39-482D-BFC7-24FCAA299648Q42532053-BFA722D4-1A8C-4FAF-9BC0-06154984E165Q46859806-9C9DD517-D384-4F96-93BE-8095ABAE4EEBQ47361141-1EE602F8-5B6C-4B08-8B54-73C1791F7FFDQ48687915-621E99E7-8669-46B5-B5FD-C402B7138D01Q52430351-B3E73194-1E1B-4AA4-BE0E-CC9910695378Q52642104-57F59F14-64D5-4B9E-8600-FEA2386FA1F9Q57314125-067EC72F-B54C-42B4-9530-2D045E942DA5
P2860
The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships.
description
1981 nî lūn-bûn
@nan
1981 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1981 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
name
The effect of quinidine and it ...... tration--effect relationships.
@ast
The effect of quinidine and it ...... tration--effect relationships.
@en
The effect of quinidine and it ...... tration--effect relationships.
@nl
type
label
The effect of quinidine and it ...... tration--effect relationships.
@ast
The effect of quinidine and it ...... tration--effect relationships.
@en
The effect of quinidine and it ...... tration--effect relationships.
@nl
prefLabel
The effect of quinidine and it ...... tration--effect relationships.
@ast
The effect of quinidine and it ...... tration--effect relationships.
@en
The effect of quinidine and it ...... tration--effect relationships.
@nl
P2093
P2860
P1476
The effect of quinidine and it ...... ntration--effect relationships
@en
P2093
L B Sheiner
P E Coates
S Riegelman
T W Guentert
P2860
P304
P356
10.1111/J.1365-2125.1981.TB01123.X
P407
P50
P577
1981-02-01T00:00:00Z